📚 BiometalDB

1921
Total papers
1310
Has abstract
1889
Has full text
🔍 Semantic Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧪 BiometalDB 🧬 Extraction

🧪 BiometalDB Articles

Enrichment: All (1921) 📝 Has abstract (1310) 📄 Has full text (1889)
Nyong-Bassey, Etubonesi E., Hicks, Andrew L., Bergin, Poppy +3 more · 2023 · Frontiers in Molecular Biosciences
Nyong-Bassey, Etubonesi E., Hicks, Andrew L., Bergin, Poppy, Tuite, Eimer M., Kozhevnikov, Valery, Veuger, Stephany Show less
Introduction: Ruthenium(II) complexes have emerged recently as candidates for anti-cancer therapy, where activity is related to lipohilicity, cellular localization, and specific interactions wi Show more
Introduction: Ruthenium(II) complexes have emerged recently as candidates for anti-cancer therapy, where activity is related to lipohilicity, cellular localization, and specific interactions with biomolecules. Methods: In this work, two novel complexes were synthesized and are reported based on the [Ru(phen)2(dipyrido[3,2-f:2',3'-h]quinoxaline]2+ framework. Results: Compared to the parent complex, annealing of cyclopenteno and cyclohexeno rings to the extended ligand substantially increased cytotoxicity towards a number of cancer cell lines, and induced apoptosis. The complexes localize in the nuclei of cancer cells and co-locate with DAPI on DNA. DNA binding studies show that both complexes bind strongly to DNA and one complex intercalates DNA like the parent, whilst the other appears to have multiple modes of interaction. Discussion: It is likely that the increased lipophilicity of the novel complexes is a key factor for increasing their cytotoxicity, rather than their DNA binding mode. Show less
📄 Full text DOI: 10.3389/fmolb.2023.1252285
Dickerson, Matthew, Sun, Yang, Howerton, Brock +1 more · 2014 · Inorganic Chemistry
Dickerson, Matthew, Sun, Yang, Howerton, Brock, Glazer, Edith C. Show less
Compounds capable of light-triggered cytotoxicity are appealing potential therapeutics, because they can provide spatial and temporal control over cell killing to reduce side effects in cancer therapy Show more
Compounds capable of light-triggered cytotoxicity are appealing potential therapeutics, because they can provide spatial and temporal control over cell killing to reduce side effects in cancer therapy. Two simple homoleptic Ru(II) polypyridyl complexes with almost-identical photophysical properties but radically different physiochemical properties were investigated as agents for photodynamic therapy (PDT). The two complexes were identical, except for the incorporation of six sulfonic acids into the ligands of one complex, resulting in a compound carrying an overall -4 charge. The negatively charged compound exhibited significant light-mediated cytotoxicity, and, importantly, the negative charges resulted in radical alterations of the biological activity, compared to the positively charged analogue, including complete abrogation of toxicity in the dark. The charges also altered the subcellular localization properties, mechanism of action, and even the mechanism of cell death. The incorporation of negative charged ligands provides a simple chemical approach to modify the biological properties of light-activated Ru(II) cytotoxic agents. Show less
📄 Full text DOI: 10.1021/ic5013796
T., Nivedya, Das, Rishav, Kumar R., Selva +9 more · 2025 · Dalton Transactions
T., Nivedya, Das, Rishav, Kumar R., Selva, Shanavas, Shanooja, Rangaswamy, Bhaskar, Aatif A, Mujthaba, Mukherjee, Chandrapaul, Roy, Riona, Sengupta, Jhimli, Bose, Bipasha, Kumar S. K., Ashok, Paira, Priyankar Show less
Title: The role of ancillary ligands on benzodipyridophenazine-based Ru(II)/Ir(III) complexes in dark and light toxicity against TNBC cells. Abstract: In this study, we investigated the impact of anc Show more
Title: The role of ancillary ligands on benzodipyridophenazine-based Ru(II)/Ir(III) complexes in dark and light toxicity against TNBC cells. Abstract: In this study, we investigated the impact of ancillary ligands on the anticancer activity of benzodipyridophenazine-based Ru(II) and Ir(III) complexes (Ru1, Ru2, Ir1, and Ir2). These metal complexes displayed three significant absorption bands attributed to the ligand-centered (LC) transitions, ligand-to-ligand charge transfer (LLCT), and metal-to-ligand charge transfer (MLCT). Binding studies of biomolecules were performed with the complexes along with the ligand, and it was found that after binding with Ru(II)/Ir(III), the properties of the ligands were enhanced. In vitro screening revealed that complex [(η5-Cp*)IrIIICl(κ2-N,N-benzo[i]dipyrido[3,2-a:2',3'-c])phenazine] (Ir1) exhibited the highest potency and selectivity (IC50 ∼ 2.14 μM, PI > 13) under yellow light irradiation. The photo-toxicity trend was Ir1 > Ru1 > Ir2 ≫ Ru2, which was found to be directly correlated with the singlet oxygen quantum yield (1O2). Chloro-substituted complexes (Ir1 and Ru1) were effective for hypoxic tumor treatment, particularly Ir1, which could generate high amounts of reactive oxygen species (ROS, type I PDT) in cells under photo irradiation. The high value of fluorescence quantum yield (fφ = 0.26) and significant emission at λ = 571 nm of Ir1 were certainly useful for bio-imaging applications. Colocalisation and DCFDA studies of Ir1 revealed that it can accumulate in the mitochondria, leading to depolarization of the mitochondrial membrane. These studies confirm that the complex Ir1 is a promising candidate for TNBC treatment in hypoxic tumors, with efficacy comparable to the current PDT drug Photofrin. Show less
📄 Full text DOI: 10.1039/d4dt03456b
Dong, Jia-Hao, Chen, Bai-Hua, Jiang, Shan +6 more · 2025 · Dalton Transactions
Dong, Jia-Hao, Chen, Bai-Hua, Jiang, Shan, Wu, Xiao-Yin, Feng, Wen-Wen, Li, Jin-Hao, Pan, Zheng-Yin, Liu, Yingju, He, Liang Show less
In recent years, photodynamic therapy (PDT) and gas therapy (GT) have emerged as research hotspots due to their excellent cancer treatment efficacy. By combining the advantages of both, the simultaneo Show more
In recent years, photodynamic therapy (PDT) and gas therapy (GT) have emerged as research hotspots due to their excellent cancer treatment efficacy. By combining the advantages of both, the simultaneous and controllable release of reactive oxygen species (ROS) and nitric oxide (NO) has become a possibility. This paper describes the design of two Ru(II) complexes, [Ru(bpy)2(NFIP)](PF6)2 (Ru1, bpy = 2,2'-bipyridine, NFIP = 4-nitro-3-trifluoromethylaniline-1H-imidazo[4,5-f][1,10]phenanthroline) and [Ru(phen)2(NFIP)](PF6)2 (Ru2, phen = 1,10-phenanthroline), through the integration of the polypyridyl ruthenium structure and a photoresponsive NO donor. The structures and purity of the complexes were confirmed by several methods, including 1H NMR, mass spectrometry, elemental analysis, high performance liquid chromatography (HPLC) and UV-Vis absorption spectra. Both complexes were demonstrated to efficiently generate singlet oxygen (1O2) (ΦΔ = 0.40 and 0.44 in phosphate buffered saline (PBS) for Ru1 and Ru2, respectively) and release NO under visible light irradiation. Upon light exposure, Ru2 exhibited significant phototoxicity against human cervical cancer HeLa cells. In vitro experiments indicated that Ru2 elevated the levels of ROS and NO in HeLa cells when exposed to light, resulting in mitochondrial impairment and caspase-mediated cell death. Overall, Ru2 proves to be a potent phototherapeutic compound, capable of producing ROS and NO, thus providing precision in cancer phototherapy. Show less
📄 Full text DOI: 10.1039/d5dt00038f
Prabaharan, Ramya, Arunachalam, Abirami, Rengan, Ramesh · 2024 · Dalton Transactions
Title: Analysis of antiproliferative activity of new half-sandwich arene Ru(II) thiophene based aroylhydrazone complexes. Abstract: Efforts in researching the efficient anti-tumor properties of three Show more
Title: Analysis of antiproliferative activity of new half-sandwich arene Ru(II) thiophene based aroylhydrazone complexes. Abstract: Efforts in researching the efficient anti-tumor properties of three novel arene ruthenium(II) complexes incorporating thiophene-based aroylhydrazone ligands have been undertaken. The complexes' elemental composition was [(η6-p-cymene)Ru(L)Cl]. They were comprehensively characterized through elemental and spectroscopic analyses (FT-IR, UV-vis, NMR, and HR-MS). Single crystal X-ray diffraction studies revealed a pseudo-octahedral geometry with bidentate coordination of the ligands in a representative complex. The in vitro assessment of the complexes' cancer cell growth inhibition was conducted using the MTT assay against A549 (human lung carcinoma), HeLa (human cervical carcinoma), HuH-7 (hepatocellular carcinoma), and NIH-3T3 (mouse fibroblast non-cancerous cell line). Results indicated significant cytotoxicity across all cancer cell lines, with IC50 concentrations of complex 2 being 6.8 μM for A549, 11.6 μM for HeLa, and 9.4 μM for HuH-7, compared to cisplatin with IC50 values of 18.9 μM, 17.68 μM, and 24 μM respectively. Notably, complex 2 demonstrated particularly promising cytotoxicity against all tested cancerous cell lines. Fluorescent staining analysis such as acridine orange/ethidium bromide (AO-EB) and HOECHST 33342 revealed cell death mechanisms involving membrane disintegration and nuclear condensation following treatment with complex 2. Further studies were conducted to measure reactive oxygen species (ROS) levels using the dichlorodihydrofluorescein diacetate (DCFH-DA) assay, and mitochondrial membrane potential (MMP) was assessed using the JC-1 dye assay. These studies demonstrated that complex 2 increased ROS levels, decreased membrane potential, and promoted mitochondrial dysfunction-mediated cell death pathways. Additionally, flow cytometry analysis, utilizing dual staining of Annexin V-FITC and propidium iodide (PI), was employed to quantitatively study apoptosis induction. Show less
📄 Full text DOI: 10.1039/d4dt01845a
Pal, Srijita, Pragti,, Kumar, Amardeep +1 more · 2025 · Dalton Transactions
Pal, Srijita, Pragti,, Kumar, Amardeep, Mukhopadhyay, Suman Show less
To overcome the undesirable side effects and acquired resistance associated with platinum-based chemotherapeutics, scientists are searching for alternative strategies involving novel metal-based compo Show more
To overcome the undesirable side effects and acquired resistance associated with platinum-based chemotherapeutics, scientists are searching for alternative strategies involving novel metal-based compounds with improved pharmacological properties. Ruthenium complexes have emerged as prospective candidates to combat side effects and improve the selectivity of anticancer agents. In this work, a benzimidazole-based chelating ligand, HL (4-(1H-naphth[2,3-d]imidazol-2-yl)-1,3-benzenediol) with O and N donor atoms, was synthesized and used for complexation with ruthenium to obtain three Ru(II) arene complexes represented by [Ru(η6-p-cym)(L)Cl], [Ru(η6-p-cym)(L)(PPh3)]+ and [Ru(η6-p-cym)(L)(PTA)]+ (where p-cym = p-cymene, PPh3 = triphenylphosphine and PTA = 1,3,5-triaza-7-phosphaadamantane). The synthesized complexes were characterized using spectroscopic techniques. UV-Vis absorption spectroscopy and LC-MS were used to study the stability of the complexes in biological medium. Their lipophilicity was studied by calculating the partition coefficient in n-octanol and water. The complexes showed significant binding with biomolecules like albumin proteins and nucleic acids. All the complexes were found to be cytotoxic, with complex [Ru(η6-p-cym)(L)PPh3]PF6 exhibiting the highest anticancer activity. The mechanism of anticancer activity was attributed to the ability of the complexes to induce apoptosis and generate reactive oxygen species (ROS). The complexes also exhibited antimetastatic properties. Furthermore, complex [Ru(η6-p-cym)(L)PPh3]PF6 was loaded onto amine-functionalized mesoporous silica nanoparticles which led to an increase in its cytotoxic activity. Show less
📄 Full text DOI: 10.1039/d4dt03536d
Khaled, Rabaa M., Abo-Elfadl, Mahmoud T., Radacki, Krzysztof +7 more · 2025 · Dalton Transactions
Khaled, Rabaa M., Abo-Elfadl, Mahmoud T., Radacki, Krzysztof, Abo Zeid, Mona A. M., Shehab, Ola R., Abdel-Kader, Nora S., Mostafa, Gamal A. E., Ali, Essam A., Al Neyadi, Shaikha S., Mansour, Ahmed M. Show less
The photo-induced CO-releasing properties of the dark-stable complex [RuCl2(CO)2L] (L = 2-(pyridin-2-yl)quinoxaline) were investigated under 468 nm light exposure in the presence Show more
The photo-induced CO-releasing properties of the dark-stable complex [RuCl2(CO)2L] (L = 2-(pyridin-2-yl)quinoxaline) were investigated under 468 nm light exposure in the presence and absence of biomolecules such as histidine, calf thymus DNA and hen egg white lysozyme. The CO release kinetics were consistent regardless of the presence of these biomolecules, suggesting that they did not influence the CO release mechanism. The quinoxaline ligand demonstrated exceptional cytotoxicity against human acute monocytic leukemia cells (THP-1), with evidence of potential DNA damage ascertained by comet assay, while it remained non-toxic to normal kidney epithelial cells derived from African green monkey (Vero) cell lines. In contrast, upon light activation, the Ru(II) complex showed no toxicity against THP-1 cells but was detrimental to Vero cells. In human colorectal carcinoma (HCT-116) cells, the ligand and the Ru(II) complex produced ROS under light and dark conditions. However, HCT-116 cells retained their ability to consume oxygen and produce ATP following CO treatment, suggesting that the ROS levels were insufficient to cause significant cellular damage. Morphological features of apoptosis, including apoptotic bodies, chromatin condensation, cell shrinkage, and membrane leakage, were observed in the presence of both the ligand and its complex, irrespective of light exposure. Show less
📄 Full text DOI: 10.1039/d4dt03082f
Liu, Xiao, Zheng, Hongwei, Peng, Yiqian +8 more · 2025 · Molecular Pharmaceutics
Liu, Xiao, Zheng, Hongwei, Peng, Yiqian, Ji, Dongliang, Wang, Chen, Wang, Dezhi, Jia, Zihan, Chang, Yingxue, Cai, Xiangming, Wang, Lei, Ling, Yong Show less
Title: Novel Ru(II) Complexes as Type-I/-II Photosensitizers for Multimodal Hypoxia-Tolerant Chemo-Photodynamic/Immune Therapy. Abstract: Photodynamic therapy (PDT) is increasingly regarded as an att Show more
Title: Novel Ru(II) Complexes as Type-I/-II Photosensitizers for Multimodal Hypoxia-Tolerant Chemo-Photodynamic/Immune Therapy. Abstract: Photodynamic therapy (PDT) is increasingly regarded as an attractive approach for cancer treatment due to its advantages of low invasiveness, minimal side effects, and high efficiency. Here, two novel Ru(II) complexes 8a,b were designed and synthesized by coordinating phenanthroline and biquinoline ligands with Ru(II) center, and their chemo-photodynamic therapy and immunotherapy were explored. Both 8a and 8b exhibited significant phototoxicity against A549 and 4T1 tumor cells via type-I/-II PDT. Among them, 8b exhibited superior oxygen-independent antitumor effects (IC50s = 1.50-1.76 μM) upon laser irradiation, and displayed micromolar-level chemotherapeutic activities, indicating its potential for chemo/photodynamic dual effects. Furthermore, 8b also initiated an ICD cascade, enhancing recruitment and maturation of antigen-presenting cells, thus triggering a CD8+ T cell antitumor immune response. Finally, in vivo antitumor experiments demonstrated that 8b exhibited significant inhibition of lung and breast tumor growth, with inhibition rates of 94.6% and 97.3%, respectively. Therefore, the Ru(II) complexes we designed, as effective type-I/-II photosensitizers and potential immunoactivators, demonstrate multiple antitumor mechanisms, warranting further study. Show less
📄 Full text DOI: 10.1021/acs.molpharmaceut.4c01046
Yakovlev, Ivan A., Golubeva, Julia A., Klyushova, Lyubov S. +2 more · 2024 · Dalton Transactions
Yakovlev, Ivan A., Golubeva, Julia A., Klyushova, Lyubov S., Kostin, Gennadiy A., Mikhailov, Artem A. Show less
Title: Photoinduced cytotoxic activity of a rare ruthenium nitrosyl phenanthroline complex showing NO generation in human cells. Abstract: A new nitro-nitrosyl complex [RuNO(Phen)(NO2)2OH] (1) was sy Show more
Title: Photoinduced cytotoxic activity of a rare ruthenium nitrosyl phenanthroline complex showing NO generation in human cells. Abstract: A new nitro-nitrosyl complex [RuNO(Phen)(NO2)2OH] (1) was synthesized and characterized by X-ray diffraction, where Phen = 1,10-phenanthroline. The complex was crystallized in two different modifications without (1) and with a solvent molecule of DMF (1a). The photolysis process together with the determination of the quantum yield of NO release was investigated in acetonitrile solution using a special flow-through system for the simultaneous registration of infrared (IR) and optical absorption (UV-vis) spectra under irradiation with 450 nm light. The quantum yield of photoinduced NO release was 4.0 ± 0.2%. DFT calculations showed that the main contribution to the absorption band at 450 nm is made by the HOMO/HOMO-1 → LUMO transitions, which are represented by the transfer of electron density from the -OH and -NO2 ligands to the orbitals located on the Ru-NO bond. The dark and photoinduced cytotoxicity of the complex was studied against the human breast adenocarcinoma (MCF-7) and lung carcinoma (A549) cell lines and human non-tumor lung fibroblasts (MRC5). The complex shows a low cytotoxicity on MCF-7 cells (ICdark50 = 90.6 ± 6.2 μM and ICirr.50 = 95.3 ± 11.4 μM) and a moderate dark cytotoxicity on A549 and MRC5 cells (ICdark50 = 33.4 ± 2.6 μM and ICdark50 = 62.6 ± 3.1 μM, respectively), which slightly increases after irradiation (ICirr.50 = 21.2 ± 3.3 μM and ICirr.50 = 47.2 ± 2.3 μM, respectively). Show less
📄 Full text DOI: 10.1039/d4dt02653e
Das, Utpal, Paira, Priyankar · 2023 · Dalton Transactions
The phototoxic nature of drugs has been seen to convey immense importance in photo activated chemotherapy (PACT) for the selective treatment of disease. Rationally, in order to eradicate the vehemence Show more
The phototoxic nature of drugs has been seen to convey immense importance in photo activated chemotherapy (PACT) for the selective treatment of disease. Rationally, in order to eradicate the vehemence of cancer in a living body, the design of phototoxic molecules has been of growing interest in research to establish a selective strategy for cancer therapy. Therefore, the present work portrays the synthesis of a phototoxic anticancer agent by incorporating ruthenium(II) and iridium(III) metals into a biologically active 2,2'-biquinoline moiety, BQ. The complexes, RuBQ and IrBQ, have been revealed as effective anticancer agents with remarkable toxicity in the presence of light compared to the dark towards HeLa and MCF-7 cancer cell lines due to the production of a profuse amount of singlet oxygen (1O2) upon irradiation by visible light (400-700 nm). Complex IrBQ exhibited the best toxicity (IC50 = 8.75 μM in MCF-7 and 7.23 μM in HeLa) in comparison to the RuBQ complex under visible light. RuBQ and IrBQ displayed considerable quantum yields (Φf) along with a good lipophilic property, indicating the cellular imaging capability of both complexes upon significant accumulation in cancer cells. Also, the complexes have shown significant binding propensity with biomolecules, viz. deoxyribonucleic acid (DNA) as well as serum albumin (BSA, HSA). Show less
📄 Full text DOI: 10.1039/d3dt01348k
Jiang, Jianrong, Chen, Qian, Huan, Tianwen +7 more · 2023 · Dalton Transactions
Jiang, Jianrong, Chen, Qian, Huan, Tianwen, Nie, Yanhong, Dai, Zhongming, Li, Dujuan, Xu, Xu, Lu, Jun, Hu, Zhangli, Xu, Hong Show less
Title: Comparative studies on Abstract: On the basis of our previous comparative studies on the DNA binding of a pair of ruthenium(II) complex enantiomers, Δ-[Ru(bpy)2PBIP]2+ and Λ-[Ru(bpy)2PBIP]2+ Show more
Title: Comparative studies on Abstract: On the basis of our previous comparative studies on the DNA binding of a pair of ruthenium(II) complex enantiomers, Δ-[Ru(bpy)2PBIP]2+ and Λ-[Ru(bpy)2PBIP]2+ {bpy = 2,2'-bipyridine, PBIP = 2-(4-bromophenyl)imidazo[4,5-f]1,10-phenanthroline}, in this study, their antitumor activities and mechanisms were further investigated comparatively. The cytotoxicity assay demonstrated that both the enantiomers exerted selective antiproliferative effects on cancer cell lines A2780 and PC3. Fluorescence localization experiments suggested that both the enantiomers effectively permeated the nucleus of HeLa cells and co-localized with DNA, resulting in their DNA damage and apoptosis. Flow cytometry experiments showed that the apoptosis was enhanced by increasing the concentration of each enantiomer. Western blotting analyses indicated that both extrinsic and intrinsic apoptosis pathways were activated by the two enantiomers. miRNA microarray analyses displayed that both the enantiomers up- and downregulated multiple miRNAs, some of which were predicted to be associated with carcinogenesis. The above experimental results also showed that the Δ-enantiomer exerted a more potent antitumor activity, a higher efficiency of entering cancer cells and a stronger apoptosis-inducing effect compared with the Λ-enantiomer. Combined with the previously published research results, experimental results from this study implied that the antitumor activity of a metal complex might have originated from the conformation change of DNA in tumor cells caused by the intercalation of the complex, that the antitumor mechanism of a metal complex could be related to its DNA-binding mode, and that the antitumor efficiency of a metal complex could result from its DNA-binding strength. Show less
📄 Full text DOI: 10.1039/d3dt01584j
Maikoo, Sanam, Xulu, Bheki, Mambanda, Allen +4 more · 2022 · ChemMedChem
Maikoo, Sanam, Xulu, Bheki, Mambanda, Allen, Mkhwanazi, Ntando, Davison, Candace, de la Mare, Jo‐Anne, Booysen, Irvin Noel Show less
Herein we illustrate the formation and characterization of new paramagnetic ruthenium compounds, trans-P-[RuCl(PPh3 )2 (pmt)]Cl (1) (Hpmt=1-((pyridin-2-yl)methylene)thiosemicarba Show more
Herein we illustrate the formation and characterization of new paramagnetic ruthenium compounds, trans-P-[RuCl(PPh3 )2 (pmt)]Cl (1) (Hpmt=1-((pyridin-2-yl)methylene)thiosemicarbazide), trans-P-[RuCl(PPh3 )2 (tmc)]Cl (2) (Htmc=1-((thiophen-2-yl)methylene)thiosemicarbazide) and a diamagnetic ruthenium complex, cis-Cl, trans-P-[RuCl2 (PPh3 )2 (btm)] (3) (btm=2-((5-hydroxypentylimino)methyl)benzothiazole). Agarose gel electrophoresis experiments of the metal compounds illustrated dose-dependent binding to gDNA by 1-3, while methylene blue competition assays suggested that 1 and 2 are also DNA intercalators. Assessment of the effects of the compounds on topoisomerase function indicated that 1-3 are capable of inhibiting topoisomerase I activity in terms of the ability to nick supercoiled plasmid DNA. The cytotoxic activities of the metal complexes were determined against a range of cancer cell lines versus a non-tumorigenic control cell line, and the complexes were, in general, more cytotoxic towards the cancer cells, displaying IC50 values in the low micromolar range. Time-dependent stability studies showed that in the presence of strong nucleophilic species (such as DMSO), the chloride co-ligands of 1-3 are rapidly substituted by the former as proven by the suppression of the substitution reactions in the presence of an excess amount of chloride ions. The metal complexes are significantly stable in both DCM and an aqueous phosphate buffer containing 2 % DMSO. Show less
📄 Full text DOI: 10.1002/cmdc.202200444
Dömötör, Orsolya, Teixeira, Ricardo G., Spengler, Gabriella +7 more · 2023 · Journal of Inorganic Biochemistry
Dömötör, Orsolya, Teixeira, Ricardo G., Spengler, Gabriella, Avecilla, Fernando, Marques, Fernanda, Lenis-Rojas, Oscar A., Matos, Cristina P., de Almeida, Rodrigo F.M., Enyedy, Éva A., Tomaz, Ana Isabel Show less
With the aim to incorporate pharmacophore motifs into the Ru(II)-polypyridyl framework, compounds [Ru(II)(1,10-phenantroline)2(2-(2-pyridyl)benzo[b]thiophene)](CF3SO3) Show more
With the aim to incorporate pharmacophore motifs into the Ru(II)-polypyridyl framework, compounds [Ru(II)(1,10-phenantroline)2(2-(2-pyridyl)benzo[b]thiophene)](CF3SO3)2 (1) and [Ru(II)(1,10-phenantroline)2(2-(2-pyridyl)benzimidazole)](CF3SO3)2 (2) were prepared, characterized and tested for their antitumor potential. The solid-state structure of the compounds was confirmed by single-crystal X-ray diffraction analysis. The solution behavior of both complexes was investigated, namely their solubility, stability, and lipophilicity in physiological mimetic conditions, as well as an eventual uptake by passive diffusion. In vitro anticancer activity of the complexes on ovarian and different colon cancer cells and apoptosis induction by the complexes were studied. A slow transformation process was observed for complex 1 in aqueous solution when exposed to sunlight, while complex 2 undergoes deprotonation (pKa = 7.59). The lipophilicity of this latter complex depends strongly on the pH and ionic strength. In contrast, 1 is rather hydrophilic under various conditions. Complex 1 was highly cytotoxic on Colo-205 human colon (IC50 = 7.87 μM) and A2780 ovarian (IC50 = 2.2 μM) adenocarcinoma cell lines, while 2 displayed moderate anticancer activity (30.9 μM and 18.0 μM, respectively). The complexes induced late apoptosis and necrosis. Only a weak binding of the complexes to human serum albumin, the main transport protein in blood serum, was found. However, a more significant binding to calf thymus DNA was observed in UV-visible titrations and fluorometric dye displacement studies. Detailed analysis of fluorescence lifetime data collected for the latter systems reveals not only the partial intercalation of the complexes, but goes beyond the usual simplified interpretations. Show less
📄 Full text DOI: 10.1016/j.jinorgbio.2022.112058
Brás, Ana Rita, Fernandes, Pedro, Moreira, Tiago +5 more · 2023 · Pharmaceutics
Brás, Ana Rita, Fernandes, Pedro, Moreira, Tiago, Morales-Sanfrutos, Julia, Sabidó, Eduard, Antunes, Alexandra M. M., Valente, Andreia, Preto, Ana Show less
Colorectal cancer (CRC) is among the most deadly cancers worldwide. Current therapeutic strategies have low success rates and several side effects. This relevant clinical problem requires the discover Show more
Colorectal cancer (CRC) is among the most deadly cancers worldwide. Current therapeutic strategies have low success rates and several side effects. This relevant clinical problem requires the discovery of new and more effective therapeutic alternatives. Ruthenium drugs have arisen as one of the most promising metallodrugs, due to their high selectivity to cancer cells. In this work we studied, for the first time, the anticancer properties and mechanisms of action of four lead Ru-cyclopentadienyl compounds, namely PMC79, PMC78, LCR134 and LCR220, in two CRC-derived cell lines (SW480 and RKO). Biological assays were performed on these CRC cell lines to evaluate cellular distribution, colony formation, cell cycle, proliferation, apoptosis, and motility, as well as cytoskeleton and mitochondrial alterations. Our results show that all the compounds displayed high bioactivity and selectivity, as shown by low half-maximal inhibitory concentrations (IC50) against CRC cells. We observed that all the Ru compounds have different intracellular distributions. In addition, they inhibit to a high extent the proliferation of CRC cells by decreasing clonogenic ability and inducing cell cycle arrest. PMC79, LCR134, and LCR220 also induce apoptosis, increase the levels of reactive oxygen species, lead to mitochondrial dysfunction, induce actin cytoskeleton alterations, and inhibit cellular motility. A proteomic study revealed that these compounds cause modifications in several cellular proteins associated with the phenotypic alterations observed. Overall, we demonstrate that Ru compounds, especially PMC79 and LCR220, display promising anticancer activity in CRC cells with a high potential to be used as new metallodrugs for CRC therapy. Show less
📄 Full text DOI: 10.3390/pharmaceutics15061731
Montel, Aline Monezi, dos Santos, Raquel Gouvêa, da Costa, Pryscila Rodrigues +3 more · 2017 · BioMetals
Montel, Aline Monezi, dos Santos, Raquel Gouvêa, da Costa, Pryscila Rodrigues, Silveira-Lacerda, Elisângela de Paula, Batista, Alzir Azevedo, dos Santos, Wagner Gouvêa Show less
Novel metal complexes have received great attention in the last decades due to their potential anticancer activity. Notably, ruthenium-based complexes have emerged as good alternative to the currently Show more
Novel metal complexes have received great attention in the last decades due to their potential anticancer activity. Notably, ruthenium-based complexes have emerged as good alternative to the currently used platinum-based drugs for cancer therapy, providing less toxicity and side effects to patients. Glioblastoma is an aggressive and invasive type of brain tumor and despite of advances is the field of neurooncology there is no effective treatment until now. Therefore, we sought to investigate the potential antiproliferative activity of phosphine-ruthenium-based complexes on human glioblastoma cell lines. Due to its octahedral structure as opposed to the square-planar geometry of platinum(II) compounds, ruthenium(II) complexes exhibit different structure-function relationship probably acting through a different mechanism from that of cisplatin beyond their ability to bind DNA. To better improve the pharmacological activity of metal complexes we hypothesized that neutron activation of ruthenium in the complexes would allow to decrease the effective concentration of the compound needed to kill tumor cells. Herein we report on the effect of unmodified and neutron activated phosphine ruthenium II complexes on glioblastoma cell lines carrying wild-type and mutated p53 tumor suppressor gene. Induction of apoptosis/authophagy as well as generation of reactive oxygen species were determined. The phosphine ruthenium II complexes tested were highly active against glioblastoma cell lines inducing cell death both through apoptosis and autophagy in a p53 independent fashion. Neutron activation of ruthenium compounds rendered them more active than their original counterparts suggesting a new strategy to improve the antitumor activity of these compounds. Show less
📄 Full text DOI: 10.1007/s10534-017-0006-1
Radulovic, S., Apostoli, P., Leone, R. +6 more · 2006 · Medicinal Chemistry
Radulovic, S., Apostoli, P., Leone, R., Zunino, F., Perego, P., Gatti, L., Carenini, N., Tesic, Z., Arandjelovic, S. Show less
The aim of this study was to investigate cellular response to several ruthenium(III), chromium(III) and rhodium(III) compounds carrying bidentate beta-diketonato ligands: [(acac)--acetylacetonate liga Show more
The aim of this study was to investigate cellular response to several ruthenium(III), chromium(III) and rhodium(III) compounds carrying bidentate beta-diketonato ligands: [(acac)--acetylacetonate ligand, (tfac)--trifluoroacetylacetonate ligand]. Cell sensitivity studies were performed on several cell lines (A2780, cisplatin-sensitive and -resistant U2-OS and U2-OS/Pt, HeLa, B16) using growth-inhibition assay. Effect of intracellular GSH depletion on cell sensitivity to the agents was analyzed in A2780 cells. Flow cytometry was used to assess apoptosis by Annexin-V-FITC/PI staining, and to analyze induction of caspase-3 activity. Possible DNA binding/damaging affinity was investigated, by inductively coupled mass spectrometry, and by 14C-thymidine / 3H-uridine incorporation assay. Cell sensitivity studies showed that the pattern of sensitivity to Ru(tfac)3 complex of the two cisplatin-sensitive/-resistant osteosarcoma cell lines, U2-OS and U2-OS/Pt, was similar to that of A2780 cells (72 h exposure), with the IC50 being around 40 microM. The growth-inhibitory effect of Ru(acac)3 ranged over 100 microM, while Cr(III) and Rh(III) complexes were completely devoid of antitumor action in vitro. Ru(tfac)3 exhibited strong potential for apoptosis induction on A2780 cells (up to 40%) and caused cell cycle arrest in the S phase as well as decrease of the percent of G1 and G2 cells. Ru(acac)3-induced apoptosis was slightly higher than 10%, whereas activation of caspase-3 in HeLa cells was moderate. DNA binding study revealed that only Cr(acac)3 was capable of binding DNA, while Cr(III) and Ru(III) compounds possess potential to inhibit DNA/RNA synthesis. In conclusion, only Ru(III) complexes showed potential for antitumor action. Show less
📄 Full text DOI: 10.2174/157340606776930718
Yang, Qingyuan, Zhang, Zhao, Mei, Wenjie +1 more · 2014 · Journal of Chemotherapy
Yang, Qingyuan, Zhang, Zhao, Mei, Wenjie, Sun, Fenyong Show less
Ruthenium complexes are widely recognized as one of the most promising DNA damaging chemotherapeutic drugs. The main goal of this study was to explore the anticancer activity and underlying mechanisms Show more
Ruthenium complexes are widely recognized as one of the most promising DNA damaging chemotherapeutic drugs. The main goal of this study was to explore the anticancer activity and underlying mechanisms of [Ru(phen)(2)(p-BrPIP)](ClO(4))(2), a novel chemically synthesized ruthenium (Ru) complex. To this end, we employed MTT assays to determine the anticancer activity of the complex, and performed single-cell gel electrophoresis (SCGE) and Western blotting to evaluate DNA damage. Our results showed that the Ru(II)-poly complex caused severe DNA damage, possibly by downregulating key factors involved in DNA repair pathways, such as proliferating cell nuclear antigen (PCNA) and ring finger protein 8 (RNF8). In addition, this complex induced cell apoptosis by upregulating both p21 and p53. Taken together, our findings demonstrate that the Ru(II)-poly complex exhibits antitumour activity by inducing cell apoptosis, which results from the accumulation of large amounts of unrepaired DNA damage. Show less
📄 Full text DOI: 10.1179/1973947813y.0000000138
Wise, Dan E., Gamble, Aimee J., Arkawazi, Sham W. +9 more · 2020 · Dalton Transactions
Wise, Dan E., Gamble, Aimee J., Arkawazi, Sham W., Walton, Paul H., Galan, M. Carmen, O'Hagan, Michael P., Hogg, Karen G., Marrison, Joanne L., O'Toole, Peter J., Sparkes, Hazel A., Lynam, Jason M., Pringle, Paul G. Show less
We report cytotoxic ruthenium(ii) complexes of the general formula [RuCl(cis-tach)(diphosphine)]+ (cis-tach = cis-cis-1,3,5-triaminocyclohexane) that have been characterised by 1H, 13C and 31P{1H} NMR Show more
We report cytotoxic ruthenium(ii) complexes of the general formula [RuCl(cis-tach)(diphosphine)]+ (cis-tach = cis-cis-1,3,5-triaminocyclohexane) that have been characterised by 1H, 13C and 31P{1H} NMR spectroscopy, mass spectrometry, X-ray crystallography and elemental analysis. The kinetics of aquation and stability of the active species have been studied, showing that the chlorido ligand is substituted by water at 298 K with first order rate constants of 10-2-10-3 s-1, ideal for potential clinical use as anti-tumour agents. Strong interactions with biologically relevant duplex and quadruplex DNA models correlate with the activity observed with A549, A2780 and 293T cell lines, and the degree of activity was found to be sensitive to the chelating diphosphine ligand. A label-free ptychographic cell imaging technique recorded cell death processes over 4 days. The Ru(ii) cis-tach diphosphine complexes exhibit anti-proliferative effects, in some cases outperforming cisplatin and other cytotoxic ruthenium complexes. Show less
📄 Full text DOI: 10.1039/d0dt02612c
Lv, Mengdi, Zheng, Yue, Dai, Xiangyu +9 more · 2024 · Journal of Medicinal Chemistry
Lv, Mengdi, Zheng, Yue, Dai, Xiangyu, Zhao, Jingyue, Hu, Guojing, Ren, Meng, Shen, Zhengqi, Su, Zhi, Wu, Chao, Liu, Hong-Ke, Xue, Xuling, Mao, Zong-Wan Show less
Chemoresistance remains an arduous challenge in oncology, but ferroptosis shows potential for overcoming it by stimulating the immune system. Herein, a novel high-performance ruthenium(II)-based arene Show more
Chemoresistance remains an arduous challenge in oncology, but ferroptosis shows potential for overcoming it by stimulating the immune system. Herein, a novel high-performance ruthenium(II)-based arene complex [Ru(η6-p-cym)(BTBpy)Cl] (RuBTB) is developed for ferroptosis-enhanced antitumor immunity and drug resistance reversal via glutathione (GSH) metabolism imbalance. RuBTB shows significantly enhanced antiproliferation activity against cisplatin (CDDP)-resistant lung cancer cells (A549R), with 26.35-fold better anticancer effects than CDDP. Immunogenic ferroptosis is induced by GSH depletion/glutathione peroxidase 4 (GPX4) inactivation, mitochondrial dysfunction, and endoplasmic reticulum (ER) stress in RuBTB-treated cells. Mechanism studies indicate that RuBTB regulates ferroptosis and immune-related pathways, coordinating with GSH metabolism-mediated glutathione S-transferase (GST) inhibition to reverse drug resistance in platinum-combined therapy. Tumor vaccination experiments demonstrate the intensified antitumor effects endowed by highly immunogenic ferroptosis in vivo. This study provides the first example of a metal-arene complex for achieving satisfactory ferroptosis therapeutic effects with efficient immunogenicity to overcome drug resistance in metal-based immunochemotherapy. Show less
📄 Full text DOI: 10.1021/acs.jmedchem.4c01467
Restrepo-Acevedo, Andrés, Murillo, María Isabel, Orvain, Christophe +7 more · 2025 · Inorganic Chemistry
Restrepo-Acevedo, Andrés, Murillo, María Isabel, Orvain, Christophe, Thibaudeau, Chloé, Recberlik, Sevda, Verget, Lucas, Gómez Vidales, Virginia, Gaiddon, Christian, Mellitzer, Georg, Le Lagadec, Ronan Show less
In recent years, photodynamic therapy (PDT) has emerged as a promising alternative to classical chemotherapy for treating cancer. PDT is based on a nontoxic prodrug called photosensitizer (PS) activat Show more
In recent years, photodynamic therapy (PDT) has emerged as a promising alternative to classical chemotherapy for treating cancer. PDT is based on a nontoxic prodrug called photosensitizer (PS) activated by light at the desired location. Upon irradiation, the PS reacts with the oxygen present in the tumor, producing cytotoxic reactive oxygen species (ROS). Compounds with highly conjugated π-bond systems, such as porphyrins and chlorins, have proven to be excellent light scavengers, and introducing a metal atom in their structure improved the generation of ROS. In this work, a series of tetrapyrrole-ruthenium(II) complexes derived from protoporphyrin IX and the commercial drug verteporfin were designed as photosensitizers for PDT. The complexes were almost nontoxic on human gastric cancer cells under dark conditions, revealing remarkable cytotoxicity upon irradiation with light. The ruthenium atom in the central cavity of the chlorin ligand allowed combined mechanisms in photodynamic therapy, as both singlet oxygen and superoxide radicals were detected. Additionally, one complex produced large amounts of singlet oxygen under hypoxic conditions. Biological assays demonstrated that the ruthenium derivatives caused cell death through a caspase 3 mediated apoptotic pathway and via CHOP, an endoplasmic reticulum stress-inducible transcription factor involved in apoptosis and growth arrest. Show less
📄 Full text DOI: 10.1021/acs.inorgchem.5c00896
James, Steffan D., Elgar, Christopher E., Chen, Dandan +8 more · 2024 · Dalton Transactions
James, Steffan D., Elgar, Christopher E., Chen, Dandan, Lewis, Matthew I., Ash, Elias T. L., Conway, Dominic S., Tuckley, Benjamin J., Phillips, Leigh E., Kolozsvári, Natália, Tian, Xiaohe, Gill, Martin R. Show less
Title: Cyrene™ as a green alternative to Abstract: Ruthenium(II) polypyridyl complexes (RPCs) that emit from triplet metal-to-ligand charge transfer (MLCT) states find a wide variety of uses ranging Show more
Title: Cyrene™ as a green alternative to Abstract: Ruthenium(II) polypyridyl complexes (RPCs) that emit from triplet metal-to-ligand charge transfer (MLCT) states find a wide variety of uses ranging from luminophores to potential anti-cancer or anti-bacterial therapeutics. Herein we describe a greener, microwave-assisted synthetic pathway for the preparation of homoleptic [Ru(N^N)3]2+ and bis-heteroleptic [Ru(N^N)2(N'^N')]2+ type complexes. This employs the bio-renewable solvent Cyrene™, dihydrolevoglucosenone, as a green alternative to N,N'-dimethylformamide (DMF) in the synthesis of Ru(N^N)2Cl2 intermediate complexes, obtaining comparable yields for N^N = 2,2'-bipyridine, 1,10-phenanthroline and methylated derivatives. Employing these intermediates, a range of RPCs were prepared and we verify that the ubiquitous luminophore [Ru(bpy)3]2+ (bpy = 2,2'-bipyridine) can be prepared by this two-step green pathway where it is virtually indistinguishable from a commercial reference. Furthermore, the novel complexes [Ru(bpy)2(10,11-dmdppz)]2+ (10,11-dmdppz = 10,11-dimethyl-dipyridophenazine) and [Ru(5,5'-dmbpy)2(10,11-dmdppz)]2+ (5,5'-dmbpy = 5,5'-dimethyl-bpy) intercalate duplex DNA with high affinity (DNA binding constants, Kb = 5.7 × 107 and 1.0 × 107 M-1, respectively) and function as plasma membrane and nuclear DNA dyes for confocal and STED microscopies courtesy of their long-lived MLCT luminescence. Show less
📄 Full text DOI: 10.1039/d4dt02676d
Zhou, Ying, Xiong, Kai, Feng, Tao +4 more · 2025 · Angewandte Chemie International Edition
Zhou, Ying, Xiong, Kai, Feng, Tao, Wu, Xianbo, Liang, Jinzhe, Chen, Yu, Chao, Hui Show less
AbstractOne of the conventional ways to eradicate tumor cells is to utilize chemotherapy agents, e.g., cisplatin, to induce DNA damage. However, DNA damage repair mechanisms can significantly limit th Show more
AbstractOne of the conventional ways to eradicate tumor cells is to utilize chemotherapy agents, e.g., cisplatin, to induce DNA damage. However, DNA damage repair mechanisms can significantly limit the therapeutic efficacy of cisplatin. These mechanisms enable tumor cells to repair the DNA damage caused by the drug, leading to resistance. Cisplatin and similar drugs bind to specific DNA sites without significantly altering their conformation. As a result, DNA repair enzymes can still attach to and repair the damaged DNA. To address this issue, we designed four Ru(II) complexes (RuC3, RuC6, RuC9, and RuC12) with high positive charges of +8 valence and regulated their nuclear accumulation levels by adjusting the length of alkyl chains. RuC9 exhibits the highest nucleus accumulation level. DNA conformation was significantly altered by inducing DNA condensation through indiscriminately neutralizing the negative charge of the DNA backbone. This significant change prevents DNA‐related enzymes from binding to DNA, ultimately leading to the efficient eradication of various tumor cell lines. To the best of our knowledge, it is the first work that kills tumor cells and overcomes cisplatin resistance through inducing DNA condensation. Show less
📄 Full text DOI: 10.1002/anie.202504970
Ywaya, David O., Ibrahim, Halliru, Friedrich, Holger B. +4 more · 2024 · Molecules
Ywaya, David O., Ibrahim, Halliru, Friedrich, Holger B., Bala, Muhammad D., Soobramoney, Lynette, Daniels, Aliscia, Singh, Moganavelli Show less
A series of new chelating bidentate (SS) alkylimidazole-2-thione-Ru(II)/Os(II) complexes (3ai, 3aii, 3aiii, 3bii/4aiiiShow more
A series of new chelating bidentate (SS) alkylimidazole-2-thione-Ru(II)/Os(II) complexes (3ai, 3aii, 3aiii, 3bii/4aiii, 4bi, 4bii), and the tridentate (SNS) pyridine-2,6-diylimidazole-2-thione-Ru(II)/Os(II) complexes (5bi, 5civ/6bi, 6ci, 6civ) in the forms [MII(cym)(L)Cl]PF6 and [MII(cym)(L)]PF6 (M = Ru or Os, cym = η6-p-cymene, and L = heterocyclic derivatives of thiourea) respectively, were successfully synthesized. Spectroscopic and analytical methods were used to characterize the complexes and their ligands. Solid-state single-crystal X-ray diffraction analyses revealed a "piano-stool" geometry around the Ru(II) or Os(II) centers in the respective complexes. The complexes were investigated for in vitro chemotherapeutic activities against human cervical carcinoma (HeLa) and the non-cancerous cell line (Hek293) using the MTT assay. The compounds 3aii, 5civ, 5bi, 4aiii, 6ci, 6civ, and the reference drug, 5-fluorouracil were found to be selective toward the tumor cells; the compounds 3ai, 3aiii, 3bii, 4bi, 4bii, and 6bi, which were found not to be selective between normal and tumor cell lines. The IC50 value of the tridentate half-sandwich complex 5bi (86 ± 9 μM) showed comparable anti-proliferative activity with the referenced commercial anti-cancer drug, 5-fluorouracil (87 ± 15 μM). The pincer (SNS) osmium complexes 6ci (36 ± 10 μM) and 6civ (40 ± 4 μM) were twice as effective as the reference drug 5-fluorouracil at the respective dose concentrations. However, the analogous pincer (SNS) ruthenium complex 5civ was ineffective and did not show anti-proliferative activity, even at a higher concentration of 147 ± 1 μM. These findings imply that the higher stability of the chelating (SS) and the pincer (SNS) ligand architectures in the complexes improves the biological (anti-proliferative) activity of the complexes by reducing the chance of ligand dissociation under physiological conditions. In general, the pincer (SNS) osmium complexes were found to be more cytotoxic than their ruthenium analogues, suggesting that the anti-proliferative activity of the imidazole-2-thione-Ru/Os complexes depends on the ligand's spatial coordination, the nature of the metal center, and the charge of the metal complex ions. Show less
📄 Full text DOI: 10.3390/molecules29050944
Khalifa, Amr, Sheweita, Salah, Namatalla, Asmaa +3 more · 2025 · Cancers
Khalifa, Amr, Sheweita, Salah, Namatalla, Asmaa, Khalifa, Mohamed, Nencioni, Alessio, Sultan, Ahmed Show less

Background/objectives

Breast cancer (BC) remains one of the most prevalent and deadly cancers worldwide, with limited access to advanced treatments in developing regions. There is a critical n Show more

Background/objectives

Breast cancer (BC) remains one of the most prevalent and deadly cancers worldwide, with limited access to advanced treatments in developing regions. There is a critical need for novel therapies with unique mechanisms of action, especially to overcome resistance to conventional platinum-based drugs. This study investigates the anticancer potential of the ruthenium complex Bis(quinolin-8-olato)bis(triphenylphosphine)ruthenium(II) (Ru(quin)2) in ER-positive (T47D) and triple-negative (MDA-MB-231) BC cell lines.

Results

Ru(quin)2 demonstrated dose-dependent cytotoxicity, with IC50 values of 48.3 μM in T47D cells and 45.5 μM in MDA-MB-231 cells. Its cytotoxic effects are primarily driven by apoptosis, as shown by increased BAX expression, enhanced caspase-3 activity, reduced Aurora B kinase levels, and elevated histone release. Ru(quin)2 also induced autophagy, evidenced by LC3-I to LC3-II conversion and reduced SQSTM1, partially mediated through MAPK signaling. Furthermore, Ru(quin)2 induced G0/G1 cell cycle arrest by downregulating cyclin D1, CDK4, and CDK6, alongside upregulation of the CDK inhibitor p21.

Conclusions

Ru(quin)2 emerges as a potent candidate for BC treatment, with multiple mechanisms of action involving apoptosis, autophagy, and cell cycle arrest. Further studies are warranted to elucidate its detailed molecular mechanisms and evaluate its therapeutic potential in vivo, moving toward clinical applications for both ER-positive and triple-negative BC management. Show less
📄 Full text DOI: 10.3390/cancers17020195
Peng, Xiaolong, Tang, Qiang, Zhu, Huiyun +3 more · 2023 · Journal of Inorganic Biochemistry
Peng, Xiaolong, Tang, Qiang, Zhu, Huiyun, Bai, Lijuan, Zhao, Hua, Chen, Yongjie Show less
Three ruthenium arene complexes, namely {[(η6-p-cymene)Ru(Cl)]2(dpb)}(PF6)2 (1), [(η6-p-cymene)Ru(dpb)Cl](PF6) (2) and [(η6 Show more
Three ruthenium arene complexes, namely {[(η6-p-cymene)Ru(Cl)]2(dpb)}(PF6)2 (1), [(η6-p-cymene)Ru(dpb)Cl](PF6) (2) and [(η6-p-cymene) Ru(dpb)py](PF6) (3) (dpb = 2,3-bis(2-pyridyl)benzo-quinoxaline, py = pyridine), were synthesized and their antitumor properties were introduced. Complexes 1-3 were characterized by 1H NMR, MS, and elemental analysis. As a binuclear ruthenium structure, the absorption of metal ligand electron transfer (MLCT) of 1 extended to 700 nm. Complex 1 was significantly hydrolyzed under dark conditions. The cytotoxicity in vitro study showed that complexes 1 and 2 are more toxic to human lung cancer cells (A549) and human cervial cancer cells (Hela) than cisplatin. Moreover, there was almost no cross-resistance between complex 1-2 and cisplatin. Under the irradiation at 478 nm, complexes 1-3 all produced singlet oxygen (1O2), and the 1O2 quantum yield of complex 1 in PBS is the highest among complexes 1-3. Complex 1 also produced 1O2 under 600 nm light irradiation. DNA gel electrophoresis showed that 1 caused the photocleavage of plasmid DNA. The hydrolysis rate of complex 1 was accelerated under light (λ > 600 nm). And the phototoxicity of complex 1 to Hela cells under light (λ > 600 nm) was much greater than its dark toxicity, which may be due to its generation of 1O2 and the promotion of its hydrolysis under long-wave light irradiation. Show less
📄 Full text DOI: 10.1016/j.jinorgbio.2023.112310
Bisceglie, Franco, Pelosi, Giorgio, Orsoni, Nicolò +5 more · 2022 · International Journal of Molecular Sciences
Bisceglie, Franco, Pelosi, Giorgio, Orsoni, Nicolò, Pioli, Marianna, Carcelli, Mauro, Pelagatti, Paolo, Pinelli, Silvana, Sadler, Peter J. Show less
We report the synthesis and characterization of three half-sandwich Ru(II) arene complexes [(η6-arene)Ru(N,N')L][PF6]2 containing arene = p-cymene, N,N' = bipyridine, Show more
We report the synthesis and characterization of three half-sandwich Ru(II) arene complexes [(η6-arene)Ru(N,N')L][PF6]2 containing arene = p-cymene, N,N' = bipyridine, and L = pyridine meta- with methylenenaphthalimide (C1), methylene(nitro)naphthalimide (C2), or methylene(piperidinyl)naphthalimide (C3). The naphthalimide acts as an antenna for photoactivation. After 3 h of irradiation with blue light, the monodentate pyridyl ligand had almost completely dissociated from complex C3, which contains an electron donor on the naphthalimide ring, whereas only 50% dissociation was observed for C1 and C2. This correlates with the lower wavelength and strong absorption of C3 in this region of the spectrum (λmax = 418 nm) compared with C1 and C2 (λmax = 324 and 323 nm, respectively). All the complexes were relatively non-toxic towards A549 human lung cancer cells in the dark, but only complex C3 exhibited good photocytoxicity towards these cancer cells upon irradiation with blue light (IC50 = 10.55 ± 0.30 μM). Complex C3 has the potential for use in photoactivated chemotherapy (PACT). Show less
📄 Full text DOI: 10.3390/ijms23147624
Liu, Tao, Pan, Chen, Shi, Huatian +5 more · 2023 · Dalton Transactions
Liu, Tao, Pan, Chen, Shi, Huatian, Huang, Tao, Huang, Yong-Liang, Deng, Yang-Yang, Ni, Wen-Xiu, Man, Wai-Lun Show less
In chemotherapy, the search for ruthenium compounds as alternatives to platinum compounds is proposed because of their unique properties. However, the geometry effect of ruthenium complexes is sparely Show more
In chemotherapy, the search for ruthenium compounds as alternatives to platinum compounds is proposed because of their unique properties. However, the geometry effect of ruthenium complexes is sparely investigated. In this paper, we report the synthesis of a series of bis(acetylacetonato)ruthenium(III) complexes bearing two amidines (1-) in a cis configuration. These complexes are highly cytotoxic against various cancer cell lines, including a cisplatin-resistant cell line. In vitro studies suggested that the representative complex can induce cell cycle G0/G1 phase arrest, decrease the mitochondrial membrane potential, elevate the intracellular reactive oxygen species level, and cause DNA damage and caspase-mediated mitochondrial pathway apoptosis in NCI-H460 cells. In vivo, it can effectively inhibit tumor xenograft growth in nude mouse models with no body weight loss. In combination with the reported trans-bis(amidine)ruthenium(III) complexes, we found that ruthenium(III) bis(amidine) complexes could be cytotoxic in both trans and cis geometries, which is in contrast to platinum-based compounds. Show less
📄 Full text DOI: 10.1039/d3dt00328k
Herrera-Ramírez, Piedad, Berger, Sarah Alina, Josa, Dana +6 more · 2023 · JBIC Journal of Biological Inorganic Chemistry
Herrera-Ramírez, Piedad, Berger, Sarah Alina, Josa, Dana, Aguilà, David, Caballero, Ana B., Fontova, Pere, Soto-Cerrato, Vanessa, Martínez, Manuel, Gamez, Patrick Show less
Two ruthenium(II) polypyridyl complexes were prepared with the {Ru(phen)2}2+ moiety and a third sterically non-hindering bidentate ligand, namely 2,2'-dipyridylamine (dpa) and N- Show more
Two ruthenium(II) polypyridyl complexes were prepared with the {Ru(phen)2}2+ moiety and a third sterically non-hindering bidentate ligand, namely 2,2'-dipyridylamine (dpa) and N-benzyl-2,2'-dipyridylamine (Bndpa). Hence, complexes [Ru(phen)2(dpa)](PF6)2 (1) and [Ru(phen)2(Bndpa)](PF6)2 (2) were characterized and their photochemical behaviour in solution (acetonitrile and water) was subsequently investigated. Compounds 1 and 2, which do not exhibit notably distorted octahedral coordination environments, contrarily to the homoleptic "parent" compound [Ru(phen)3](PF6)2, experience two-step photoejection of the dpa and Bndpa ligand upon irradiation (1050-430 nm) for several hours. DNA-binding studies revealed that compounds 1 and 2 affect the biomolecule differently upon irradiation; while 2 solely modifies its electrophoretic mobility, complex 1 is also capable of cleaving it. In vitro cytotoxicity studies with two cancer-cell lines, namely A549 (lung adenocarcinoma) and A375 (melanoma), showed that both 1 and 2 are not toxic in the dark, while only 1 is significantly cytotoxic if irradiated, 2 remaining non-toxic under these conditions. Light irradiation of the complex cation [Ru(phen)2(dpa)]2+ leads to the generation of transient Ru species that is present in the solution medium for several hours, and that is significantly cytotoxic, ultimately producing non-toxic free dpa and [Ru(phen)(OH2)2]2+. Show less
📄 Full text DOI: 10.1007/s00775-023-01998-z
Pan, Nanlian, Zhang, Yuqing, Huang, Minying +7 more · 2024 · JBIC Journal of Biological Inorganic Chemistry
Pan, Nanlian, Zhang, Yuqing, Huang, Minying, Liang, Zhijun, Gong, Yao, Chen, Xide, Li, Yuling, Wu, Ciling, Huang, Zunnan, Sun, Jing Show less
Transition metal complexes with characteristics of unique packaging in nanoparticles and remarkable cancer cell cytotoxicity have emerged as potential alternatives to platinum-based antitumor drugs. H Show more
Transition metal complexes with characteristics of unique packaging in nanoparticles and remarkable cancer cell cytotoxicity have emerged as potential alternatives to platinum-based antitumor drugs. Here we report the synthesis, characterization, and antitumor activities of three new Ruthenium complexes that introduce 5-fluorouracil-derived ligands. Notably, encapsulation of one such metal complex, Ru3, within pluronic® F-127 micelles (Ru3-M) significantly enhanced Ru3 cytotoxicity toward A549 cells by a factor of four. To determine the mechanisms underlying Ru3-M cytotoxicity, additional in vitro experiments were conducted that revealed A549 cell treatment with lysosome-targeting Ru3-M triggered oxidative stress, induced mitochondrial membrane potential depolarization, and drastically reduced intracellular ATP levels. Taken together, these results demonstrated that Ru3-M killed cells mainly via a non-apoptotic pathway known as oncosis, as evidenced by observed Ru3-M-induced cellular morphological changes including cytosolic flushing, cell swelling, and cytoplasmic vacuolation. In turn, these changes together caused cytoskeletal collapse and activation of porimin and calpain1 proteins with known oncotic functions that distinguished this oncotic process from other cell death processes. In summary, Ru3-M is a potential anticancer agent that kills A549 cells via a novel mechanism involving Ru(II) complex triggering of cell death via oncosis. Show less
📄 Full text DOI: 10.1007/s00775-023-02039-5
Travassos, Ingrid O., Mello-Andrade, Francyelli, Caldeira, Raíssa P. +7 more · 2021 · JBIC Journal of Biological Inorganic Chemistry
Travassos, Ingrid O., Mello-Andrade, Francyelli, Caldeira, Raíssa P., Pires, Wanessa C., da Silva, Paula F. F., Correa, Rodrigo S., Teixeira, Tamara, Martins-Oliveira, Alisson, Batista, Alzir. A., de Silveira-Lacerda, Elisângela P. Show less
Metal complexes based on ruthenium have established excellent activity with less toxicity and great selectivity for tumor cells. This study aims to assess the anticancer potential of ruthenium(II)/all Show more
Metal complexes based on ruthenium have established excellent activity with less toxicity and great selectivity for tumor cells. This study aims to assess the anticancer potential of ruthenium(II)/allopurinol complexes called [RuCl2(allo)2(PPh3)2] (1) and [RuCl2(allo)2(dppb)] (2), where allo means allopurinol, PPh3 is triphenylphosphine and dppb, 1,4-bis(diphenylphosphino)butane. The complexes were synthesized and characterized by elemental analysis, IR, UV-Vis and NMR spectroscopies, cyclic voltammetry, molar conductance measurements, as well as the X-ray crystallographic analysis of complex 2. The antitumor effects of compounds were determined by cytotoxic activity and cellular and molecular responses to cell death mechanisms. Complex 2 showed good antitumor profile prospects because in addition to its cytotoxicity, it causes cell cycle arrest, induction of DNA damage, morphological and biochemical alterations in the cells. Moreover, complex 2 induces cell death by p53-mediated apoptosis, caspase activation, increased Beclin-1 levels and decreased ROS levels. Therefore, complex 2 can be considered a suitable compound in antitumor treatment due to its cytotoxic mechanism. Show less
📄 Full text DOI: 10.1007/s00775-021-01862-y